Company Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (M) Investors; Placement Agents; Details (Date)
Aastrom Biosciences Inc. Convertible preferred stock and warrants 3,000 preferred shares; warrants for 0.3M shares of common stock 3 Placement consists of $3M worth of 1999 Series III convertible preferred stock, yielding 5.5%; conversions are based on 0% to 6% discount to market price of Aastrom common stock; maximum conversion price is $2.34; in addition the undisclosed single investor received 5-year warrants to purchase 0.3M shares of common stock (6/3)
Abgenix Inc. Private placement of common stock 1.8S 75 Abgenix sold 1.8M shares of common stock to selected institutional and other accredited investors at $42 per share; Pacific Growth Equities served as placement agent (11/15)
Access Pharmaceuticals Inc. Private placement of common stock 1.5S 3 First closing of a planned financing for up to $8M; placement consists of $3M worth of common stock; in connection with the financing, Access will add three new members to its board of directors (7/21)
Advanced Viral Research Corp. Private placement of convertible debentures and warrants 1W $2.3E Advanced Viral made a private placement in the form of a $2M, ten-year 7% convertible debenture to Focus Investors LLC; in addition, Focus has been granted 1M warrants to purchase additional shares at approximately $0.25 per share (8/5)
Affymetrix Inc. Private placement of common stock 1S 32.5 Undisclosed institutional investor bought 1M common shares for $32.50 each, for a total of $32.5M (3/15)
Affymetrix Inc. Private placement of convertible subordinated notes - 150 Affymetrix completed the private placement of $125M principal amount of 5% convertible subordinated notes with an undisclosed entity that exercised its option to purchase an additional $25M of notes for gross pro ceeds of $150M; the notes are convertible, subject to adjustment under certain circumstances, into Affymetrix common stock at a price equal to $123 per share (9/17)
Amarillo Biosciences Inc. Conversion of debt into equity 0.95S 2.8 Hyashibara Biochemical Laboratories converted 2 loans totaling $2.6M (plus $0.24M in interest) into equity, receiving 0.95M shares at $3 per share; conversion raises HBL's stake in Amarillo from 23% to 34.3% (4/5)
Amylin Pharmaceuticals Inc. Private placement of preferred stock 0.125S 15 Amylin issued 0.125M shares of Series A preferred stock at $120 per share, raising $15M; each share is convertible into common stock at an initial conversion rate of 100 shares of common stock per Series A preferred share; the preferred shares will automatically be converted into common stock if the closing bid price of the common shares remains above $2.40 for 30 consecutive trading days; dividends on the preferred shares will accrue at a rate of 5% per year (3/24)
Amylin Pharmaceuticals Inc. Sale of division - 2.6 Amylin sold its Cabrillo Laboratories division to Magellan Laboratories Inc. for a cash payment of $2.1M and a $0.5M credit for future laboratory services (5/4)
Amylin Pharmaceuticals Inc. Private placement of common stock 3.7S 18.5 Amylin raised $18.5M in a private placement of 3.7M shares of common stock at $5 per share; investors included members of the company's board of directors and their affiliated funds (10/7)
Aphton Corp. Private placement of common stock 0.8S 11.2 Aphton raised $11.2M in a private placement of 0.8M shares of common stock, at $14 per share, to an undisclosed institutional investor; the share price of $14 was the market price at the time the terms were negotiated (10/13)
Aquila Biopharmaceuticals Inc. Direct limited placement of newly issued shares of common stock 0.7S 1.5 Aquila completed a direct, limited placement in which it sold 0.7M shares of common stock to the State of Wisconsin Investment Board (7/21)
Aradigm Corp. PIPE 2.4S 25.5 Aradigm sold 2.4M newly issued shares of common stock at $10.625 each to institutional investors, including The Kaufmann Fund Inc., Hambrecht & Quist Capital Management Inc., Bank Invest, Delta Opportunity Fund and Zesiger Capital Group LLC. The company will register the shares for resale. Piper Jaffray Inc. and Petkevich & Partners LLC served as advisors to Aradigm (3/15)
Aronex Pharmaceuticals Inc. Institutional offering of registered stock 6.0S 13.1 Aronex sold 6M shares of newly registered common stock at $2.1875 each to selected investors; the company offered the shares on an all-or-none basis; Paramount Capital Inc. acted as the placement agent (2/24)
Avanir Pharmaceuticals Equity line - 10 Avanir secured a $10M equity line from Promethean Investment Group LLC; Avanir can access the $10M over 2 years by selling common stock at threshold prices (to be set by Avanir); pricing above threshold is at a discount to market; no transaction occurs if the stock price is below $1.064 per share; Avanir will register the shares for resale (1/25)
Avant Immunotherapeutics Inc. Private placement of common stock 5.5S 10.5 Avant closed a private placement of 5.5M shares of common stock at $1.92 per share; Nomura International plc acted as placement agent (9/22)
AVAX Technologies Inc. Private placement of shares and warrants 0.1S, 0.62W 10.1 AVAX completed a private placement with Essex Woodlands Health Ventures Fund IV L.P., Petrus Fund L.P. (an affiliate of Perot Investments) and others; AVAX issued 0.1M shares of Series C convertible preferred stock with a conversion price of $3.25; purchasers received warrants to buy 0.31 shares of common stock with an exercise price of $4 and 0.31 shares with an exercise price of $4.50; warrants are exercisable over 5 years (3/3)
AVI Biopharma Inc. Private placement of common stock ND 6.5 AVI sold $6.5M of common stock to five institutional investors who were granted the additional opportunity to invest $2.2M through the exercise of warrants; placement agents were European American Securities Inc. and Cruttenden-Roth; lead investor was The Tail Wind Fund Ltd. (12/22)
Avigen Inc. Private placement ND 5.8 Avigen sold $5.8M in common stock and warrants to investors from the U.S., Europe and Hong Kong; the investor group bought the common shares in multiple closings, with shares in each closing priced at market; for every 5 shares, the investors got a 5-year warrant to purchase 1 share of common stock at a 25% premium to market; the company will register the underlying shares for resale (1/11)
Avigen Inc. Private placement of common stock and warrants 2.2S; 0.44W 13.1 Avigen completed a placement of 2.2M shares of common stock at prices from $5.50 to $6; for every 5 shares purchased, investors get one 5-year warrant to purchase 1 common share at a premium to the price paid in this placement; the investors, all non-U.S., were not disclosed (5/4)
Avigen Inc. Private placement of common stock and warrants ND 40 Avigen sold an undisclosed amount of common stock and warrants to a group of investors from the United States and Europe; the investor group purchased shares of the common stock in multiple closings at per-share purchase prices equal to the closing prices on the Nasdaq National Market on the respective days of closing; for every five shares purchased, each investor also receives a five-year warrant to purchase one share of common stock at a 25 percent premium to the respective closing price (11/16)
Aviron Private placement of common stock 0.4S $6E Aviron sold 0.4M shares of its common stock to an undisclosed financial institution; further details ND (11/18)
Aviron Private placement of common stock 0.26S 5.3 Aviron sold 0.26M shares of its common stock at $15.48 per share to an undisclosed financial institution (12/16)
Axonyx Inc. Private placement of common stock and warrants 170 units of 0.004S and 0.002W 4.25 Axonyx sold 170 units at $0.025M to an undisclosed investor; each unit consists of 0.004M shares of restricted common stock and 0.002M five-year warrants, exercisable at $11.00 (11/2)
BioChem Pharma Inc. Sale of diagnostics subsidiary - ND BioChem Pharma will sell the hematology operations of its diagnostics subsidiary, Biochem Immunosystems Inc., to ABX Diagnostics Inc. (7/7)
Bio-Technology General Corp. Exercise of warrants 3.1W 17 The company received $17M on the exercise of 3.1M common stock purchase warrants, which were issued in 12/93 as part of a private placement with Biocardia Corp.; the warrants had an exercise price of $5.49 per Bio-Technology General share (1/6)
BioTime Inc. Rights offer 0.75S 7.3 BioTime completed oversubscribed rights offer, raising $7.3M through the sale of 0.75M shares, including 0.25M shares to fill oversubscriptions; shareholders received one right per share; rights holders could purchase one common share for every 20 rights owned at a subscription price of $9.75 per share (3/11)
BioTransplant Inc. Private placement of common stock 1.7S 7.7 BioTransplant sold approximately 1.7M shares of its common stock to selected institutional investors at $4.50 per share; Evolution Capital, a subsidiary of the Carson Group, acted as placement agent (12/29)
Boston Biomedica Inc. Private placement of common stock purchase warrants 0.5W 2.2 Boston Biomedica completed a private placement of common stock purchase warrants to the Paradigm Group, of Northbrook, Ill.; the placement consisted of 0.4M common stock purchase warrants with an exercise price of $4.25, and 0.1M common stock purchase warrants with an exercise price of $5.25; National Securities Corp. acted as placement agent for Boston Biomedica (8/19)
Boston Life Sciences Inc. Private placements 2.19S 8.5 The company raised $8.5M total in 2 private placements; in the first placement, it sold $4.4M in convertible preferred stock; the $19.50 shares can be converted into 5 shares of common stock; an additional $1.6M is being held in escrow; the total of $6M from this placement may be converted into 1.54M sharesof common stock; the company will register the underlying shares for resale; this 1st placement was managed by Josephthal & Co. Inc.; in the 2nd placement, the company raised $2.5M by issuing 0.65M shares of common stock and 0.1M purchase warrants; the company will also register these shares; the institutional investors in these placements included CIBC Oppenheimer and The Tail Wind Fund (2/16)
Boston Life Sciences Inc. Private placement of convertible debentures - 8 Boston Life completed a private placement of $8M in convertible debentures with a single institutional investor; H.C. Wainwright & Co. acted as placement agent (9/22)
Calypte Biomedical Corp. Private placement of common stock 3.4S $7E Calypte Biomedical sold 3.4M common shares at approximately $2 each, raising an estimated $7M; Pacific Growth Equities acted as placement agent (3/26)
Celgene Corp. Convertible notes - 15 Celgene placed $15M principal amount of convertible notes with John Hancock Mutual Life Insurance Co. and several of its affiliates; the notes are convertible into common stock at $18.00 per share, beginning 1/00; Warburg Dillon Read LLC acted as the placement agent (1/21)
Celgene Corp. Convertible notes - 15 Celgene placed $15M principal amount of convertible notes with John Hancock Mutual Life Insurance Company and several of its affiliates; the notes are convertible beginning 7/00 at $19 per share (7/12)
Cellegy Pharmaceuticals Inc. Private placement of common stock 1.6S 10.1 Cellegy completed a private placement of 1.6M shares of its common stock; existing investors included the Tisch Family Interests, GMT Capital Corp. and K. Michael Forrest; new investor was Janus Global Life Sciences Fund; the transaction was self-managed by Cellegy (8/2)
Cellex Biosciences Inc. Debtor-inpossession financing - 0.9 Under its plan of reorganization, Cellex received a cash investment from Biovest LLC of $265,000 and the payment of approximately $700,000 to a secured creditor of the company; the plan provides for Biovest to gain equity control of Cellex, with 25% of the company's new common stock to be issued to its unsecured creditors; all prior equity interests in the debtor will be canceled as of the plan's effective date of 7/30/99 (7/13)
Celsion Corp. Exercise of warrants - 1 More than 90% of Celsion's Series 700 warrant holders exercised their warrants (8/30)
Cell Pathways Inc. Private placement of common stock 1.5S 14 Cell Pathways raised $14M in a private placement of common stock at $9 per share; for each share purchased, the buyers also received one warrant enabling them to purchase an additional share of common stock at $14 per share; placement agent was Janney Montgomery Scott; other participants included four funds managed by Morgan Stanley Dean Witter Investment, including the Van Kampen American Value Fund; one fund managed by Miller, Anderson & Sherrerd LLP; and two funds managed by AIG Capital Management; previous investors included Vulcan Ventures Inc. and Jackson Boulevard Capital Management (10/11)
Cell Therapeutics Inc. Private placement of convertible preferred stock - 10 Cell Therapeutics sold $10M of its Series A convertible preferred stock, convertible to 4.6M shares of common stock; in connection with the financing, the company issued warrants to the investor group to purchase 1.4M shares of common stock at $2.87 per share; lead investor was Essex Woodlands Health Ventures Fund (11/16)
Cel-Sci Corp. Private placement of common stock ND 2.5 Cel-Sci sold $2.5M of its common stock to two undisclosed institutional investors; Reedland Capital Partners, a division of Financial West Group, acted as placement agent (12/14)
Cephalon Inc. Revenuesharing notes - 30 Cephalon raised $30M in a debt offering by selling revenue-sharing notes to The Kaufmann Fund, The Sprout Group and Delta Opportunity Fund; the interest-bearing notes (11% annually) are repayable by the company in cash in 2/02 and are secured by the company's U.S. rights to Provigil (for treating narcolepsy); the investors will get a 6% royalty on U.S. sales of the product for up to 5 years; the notes are not convertible into common stock; Cephalon also issued 1.92M 5-year warrants to purchase shares of common stock at $10.08 each (a 25% premium to market); Diaz & Altschul Capital LLC acted as the placement agent (2/25)
Cephalon Inc. Private placement of convertible, exchangeable preferred stock 2S 100 Cephalon entered into a purchase agreement providing for the sale to certain initial purchasers of 2M shares of convertible, exchangeable preferred stock at $50 per share; the company has granted the initial purchasers a 45-day option to purchase up to an additional 0.5M shares of the preferred stock; the preferred stock will be convertible into shares of common stock at a conversion price of $17.92 per share, subject to adjustment in certain circumstances (8/13)
Cephalon Inc. Private placement of convertible, exchangeable preferred stock 0.5S 25 The initial purchasers of Cephalon's previously announced offering of 2M shares of convertible exchangeable preferred stock at $50 per share exercised in full their overallotment option to purchase an additional 0.5M shares at $50 per share; shares of the preferred stock are convertible at a rate of $17.92 per share, and are redeemable at the option of the company in two years; exercise of the overallotment option brings the total amount of the original offering to $125M (9/27)
Cerus Corp. Private placement of common stock 1S 25 Cerus sold 1M shares of its common stock to selected institutional and other accredited investors at $25 per share; Prudential Vector Healthcare Group, a subsidiary of Prudential Securities Inc., acted as placement agent (12/21)
Cocensys Inc. Sale of stake in Cytovia Inc. - 3.3 Cocensys sold its stake in Cytovia Inc. spinoff for $3.3M to entities affiliated with Domain Associates LLC; Cytovia will use proceeds to repurchase $3.18M worth of its Series E convertible preferred stock (5/18)
CollaGenex Pharmaceuticals Inc. Private placement of convertible preferred stock - 20 Investor group led by OCM Principal Opportunities Fund LP signed preliminary agreement to buy $20M worth of Series D convertible preferred stock, which may be converted into common stock at an exercise price of $11 per share; during the first 3 years following issuance, holders will be entitled to dividends payable in common stock at a rate of 8.4% per annum (8%, paid in cash, thereafter); financing to be presented at CollaGenex's 5/11 annual shareholder meeting (3/19)
Collateral Therapeutics Inc. Private placement of common stock 2.2S 33.9 Collateral completed a private placement of 2.2M shares of unregistered common stock to selected institutional and accredited investors (8/12)
Corixa Corp. Equity-based credit line 50 Castle Gate LLC will provide up to $50M of equity capital under a 2-year credit line, with an initial draw of $12.5M (12,500 shares of Series A preferred stock at $1,000 per share, convertible at fixed exchange of $8.50 per share); conversion rates on future draws will be based upon average closing price of Corixa stock before and after the draw date; dividends on on the convertible stock will accrue at 5% per year, payable in stock or cash at Corixa's option (4/9)
Corvas International Inc. Private placement of common stock and convertible note 1.3S 9.75 Corvas received $6.5M in the placement of a seven-year, senior subordinated convertible note with an effective interest rate of 5.6%; the notes are convertible into shares of common stock at $3.25 per share at the option of the holder; Corvas may call the notes for redemption any time after August 18, 2002; an additional $3.25M was received from the sale of 1.3M shares of common stock to Sofinov, Societe financiere d'innovation, a subsidiary of the Caisse de depot et placement du Quebec, of Montreal; to International Biotechnology Trust, of London; and to a current Corvas stockholder (8/20)
Corvas International Inc. Private placement of common stock and securities 0.7S 5.25 Corvas raised $5.25M from four investors; $3.5M was raised from the sale of securities to Artisan Equity Ltd.; $1.75M was raised from the sale of 0.7M shares of common stock to Sofinov (Societe financiere d'innovation), Finsbury Technology Trust and a fund associated with Wanger Asset Management (10/22)
Cubist Pharmaceuticals Inc. Private placement of common stock 2.5S 18.8 Cubist raised $18.8M in a private placement of common stock at $7.50 per share; Pacific Growth Equities acted as placement agent; other investors included new and existing shareholders (10/15)
CuraGen Corp. Private placement of common stock 1.5S 15 CuraGen completed a private placement of 1.5M shares of common stock at $10 per share to funds managed by Pequot Capital Management Inc. (9/8)
Cypress Bioscience Inc. Exercise of publicly traded warrants 2.8W 5.2 Approximately 2.6M of 2.8M outstanding publicly traded warrants have been exercised, with proceeds to Cypress of $5.2M; warrants were called for redemption on 3/17; those not exercised by 4/19 were redeemed at $0.10 per warrant on 4/19 (4/21)
Cytel Corp. Sale of Glytec business unit - 5 Neose Technologies Inc. acquired the carbohydrate manufacturing patents, licenses and other intellectual property of Cytel's Glytec business unit; Neose paid $3.5M in cash and put an additional $1.5M in escrow, the release of which is contingent upon satisfaction of matters related to the acquired patents and licenses; Neose may pay up to an additional $1.6M, depending on how much it gets in future collaborations using the technology (3/29)
Cytogen Corp. Private placement 6S 4.5 Cytogen sold $4.5M in registered stock to its 2 largest stockholders (a subsidiary of The Hillman Co. and the State of Wisconsin Investment Board); the company sold 6M shares of common stock at $0.75 each (1/6)
Cytogen Corp. Private placement of common stock 3.1S 5 Cytogen completed a private placement of common stock to the State of Wisconsin Investment Board; the company sold 3.1M shares at $1.61 per share, equal to a 7.25% discount to the average price of shares over an agreed five-day pricing period (8/5)
Diatide Inc. Private placement 0.83S 6 Diatide sold $6M of convertible preferred stock to 2 unnamed investors; the stock is convertible at $7.27 per share into 825,309 shares of common stock; the investors also got 2-year warrants to buy 123,795 shares of common stock at $8.72 each; the company may be required to register the underlying common stock any time after 1 year (1/21)
Digene Corp. Private placement of common stock 1.5S 19.5 Digene and certain of its stockholders entered into definitive agreements for the private placement of an aggregate of 1.5M shares of common stock to selected institutional and other accredited investors; 0.9M shares will be sold by the company, and 0.6M shares will be sold by the selling stockholders, all at $13 per share (11/19)
Digene Corp. Private placement of common stock 1.5S 19.5 Digene and certain of its stockholders sold 1.5M shares of common stock to selected institutional and other accredited investors at $13 per share; Prudential Vector Healthcare Group acted as placement agent (12/28)
Discovery Laboratories Inc. Private placement of common stock and warrants - 2.45 Unit offering consisted of common stock priced at market with warrants priced at a premium to market; lead investor OrbiMed Advisors LLC, of New York, made an investment totaling $2M (7/30)
DNAP Holding Corp. Loan - 30 DNAP completed a $30M 1-year term credit commitment with the Bank of Montreal; the loan facility is guaranteed by Empresas La Moderna SA de CV, DNAP's parent company (1/6)
Dusa Pharmaceuticals Inc. Private placement 1.5S 7.5 Dusa sold 1.5M unregistered shares of common stock at $5.00 each (a 15.6% discount to market) to existing and new institutional and other accredited investors (1/14)
Endorex Corp. Line of credit - 0.8 Endorex completed a $0.75M financing agreement with Finova Capital Corp.; Endorex will get the money in the form of secured equipment loans over 12 months (it drew down the 1st $0.3M on 12/31/98) (1/7)
Endovasc Ltd. Debt financing - 0.5 Endovasc secured $0.5M in the form of a debt instrument through Portfolio Strategic Advisors (1/19)
EntreMed Inc. Private placement of common stock and two series of warrants - 25 EntreMed issued shares of common stock at a 7.5% discount to a five-day averaged market price, and two series of warrants with an exercise price at a premium to the present market price; the warrants may be called by EntreMed if the market price for the common stock reaches certain levels; First Security Van Kasper acted as placement agent; buyers are institutional investors and existing shareholders who expressed interest in such a transaction (7/28)
Epoch Pharmaceuticals Inc. Private placement of stock 1.25S 3 Epoch raised $3M in a private financing at a price of $2.50 per share; investors included PE Corp., Bay City Capital, Grace Brothers Ltd. and Hilspen Capital Management; further details ND (11/3)
Gensia Sicor Inc. Private placement of units 8.70U 35 Investors included Carlo Salvi, president and CEO; Gensia Sicor sold or received near-term commitments for 8.675M units at $4 each; each unit consists of 1 share of common stock and a warrant to purchase 1/10 share of common stock at a per-share exercise price of $5.75; Gensia used $10M of the proceeds to repay Salvi's 12/98 loan to the company (5/21)
Genta Inc. Sale of subsidiary - 6.2 Genta sold its JBL Scientific Inc. subsidiary to Promega Corp.; terms included a cash payment of $5M, a promissory note of $1.2M (subject to offset under certain circumstances), and pharmaceutical development services supporting Genta's G3139 cancer compound (5/11)
Genta Inc. Private placement of units - 11.4 Genta sold 114 units in a private placement, raising $11.4M; each unit consisted of 0.033M shares of common stock, and warrants to purchase 8,333 shares of common stock at any time prior to the fifth anniversary of the closing; further details ND (12/23)
Genzyme Transgenics Corp. Private placement of common stock ND 5.4 Genzyme completed a private placement of previously registered shares of common stock with two institutional investors, TriMark Holdings and The Special Situations Fund (12/15)
Geron Corp. Sale of convertible debentures and warrants - 12.5 Geron entered into an agreement with an ND institutional investor to sell $12.5M in convertible debentures; the debentures are convertible by the investor at a fixed conversion price of $10.25 per share; the debentures convert at the company's option when the common stock has a traded at a certain premium to the fixed conversion price for five consecutive trading days; the investor will receive warrants to purchase up to 1.1M shares of common stock at a premium to the current market price; the warrants will expire 18 months following the closing (10/1)
Guilford Pharmaceuticals Inc. Private placement of common stock 3.4S 45 Guilford completed the sale of an aggregate of 3.4M newly issued shares of common stock to institutional and other accredited investors at $13.50 per share; Prudential Vector Healthcare Group, a unit of Prudential Securities Inc., served as placement agent (9/24)
Helix BioMedix Inc. Private equity financing ND 2 Helix completed a private placement of approximately $2M in equity financing; further details ND (10/20)
Heska Corp. Private placement of common stock 6.5S 13.3 Heska sold 6.5M shares of its common stock to several institutional investors, including the State of Wisconsin Investment Board, Charter Ventures II LP and Zesiger Capital Group LLC (12/3)
Hollis-Eden Pharmaceuticals Inc. Private placement 0.72S 13 The company sold 719,220 shares of common stock at $18.075 each to an investment group led by Capital Research and Management Co. (1/26)
Hollis-Eden Pharmaceuticals Inc. Private placement 0.65S 12 The company sold 648,649 shares of common stock at $18.50 each to individual investor Robert Petersen (1/31)
Human Genome Sciences Inc. Convertible notes - 100 HGS placed $100M principal amount of 5.5% convertible subordinated notes due 2006; notes are convertible to common stock at $52.50 per share (6/22)
Human Genome Sciences Inc. Convertible notes - 25 The initial purchaser of the company's recently completed private placement of $100M principal amount of 5.5% convertible subordinated notes due 2006 exercised its option and purchased an additional $25M of notes; the notes are convertible into common stock at $52.50 per share (7/23)
Human Genome Sciences Private placement of notes - 200 HGS completed a private placement of $150M principal amount of 5% convertible subordinated notes due 2006; the notes are convertible into HGS common stock at a price equal to $143.25 per share, subject to adjustment under certain undisclosed circumstances; following completion of the placement, the initial purchaser, Credit Suisse First Boston, exercised its option to purchase an additional $50M of notes, subject to the terms of the original placement (12/22)
Hyal Pharmaceutical Corp. Sale of ownership in subsidiary - 1.3 Hyal sold its entire interest in its 60%-owned subsidiary Hyal Pharmaceutical Australia Ltd. to a number of independent buyers; the sale was made through the facilities of the Australian Stock Exchange; Hyal received US$1.3M in proceeds (prices converted at a rate of C$1.51/ US$1) (1/7)
ID Biomedical Corp. Private placement of warrants 2W C$5.5 (US$3.76) ID Biomedical raised C$5.5M (US$3.76) in a private placement of special warrants to an undisclosed investor; each warrant will be exercisable, without additional payment, into one common share and one-half of one common share purchase warrant; each whole warrant will entitle the holder to purchase an additional common share at the price of C$2.75 (US$1.88) per share for a period of three years after the closing date of the issuance of the warrants (10/1)
Idec Pharmaceuticals Corp. Liquid yield option notes - 115 Idec sold $345M aggregate principal amount (including the overallotment option, which was exercised 3/1/99) in liquid yield option notes (LYONS) due 2019; the company received $115M from the private placement; the 20-year convertible zero-coupon subordinated notes were priced with a yield to maturity of 5.5% per year; each $1,000 note is convertible at any time into 6.734 shares of Idec common stock at an initial price of $50.17; the company may redeem the securities for cash on or after 2/16/04; Merrill Lynch & Co. served as the placement agent (2/10; 3/1)
IGEN International Inc. Debt financing - 30 IGEN raised $30M in debt financing with John Hancock Mutual Life Insurance Company; financing has 7-year term with interest rate of 8.5%; ING Barings Furman Selz LLC acted as placement agent (3/23)
Ilex Oncology Inc. Private placement of common stock 2.4S 20 Ilex completed a $20M private placement of 2.4M shares of common stock; participants in the financing included Alta Partners, Advent International, and Chase Capital and McCombs Enterprises (7/19)
The Immune Response Corp. Private placement of common stock 0.6S 3 Immune Response raised $3M in a private placement of 0.6M shares of common stock, at $5.06 per share, to an undisclosed institutional investor; the final number of shares to be issued to the investor will be determined by using a price equal to a 6 percent discount to the average trading price of the company's common stock during the 20 trading days following the sale of the shares; the company has agreed to sell the investor an additional $2.5M of common stock with no obligation to buy (10/22)
The Immune Response Corp. Private placement of common stock 0.8S 3.1 Immune Response sold 0.8M shares of common stock to an institutional investor at $4 per share, a 6 percent discount to the average of the weighted average trading price of the company's common stock during the 20-trading-day period ended 11/18 (11/23)
Immunomedics Inc. Private placement of common stock 2.5S 7.5 Immunomedics sold 2.5M shares of its common stock to Paramount Capital, of New York, at $3 per share (12/15)
Inex Pharmaceuticals Corp. Private placement of warrants 5.5W (US$7.5)* C$11M INEX closed the first, $11M tranche of a $12M offering; the company issued 5.5M warrants at $2 each; each warrant is exchangeable for 1 common share without additional payment; Yorkton Securities Inc. and Goepel McDermid Inc. are agents (5/27)
Inex Pharmaceuticals Corp. Special warrant financing 6W C$12 (US$8) Six million special warrants were sold on a private placement basis by Inex's agents, Yorkton Securities Inc. and Goepel McDermid Securities Inc.; each special warrant is exchangeable into one common share without additional payment (8/9)
Inflazyme Pharmaceuticals Ltd. Release of special warrants funds - C$15.5 (US$10.5) Conditional listing on Toronto Stock Exchange permitted release from escrow of gross proceeds of C$15.5M from special warrants sale in May (6/28)
Inhale Therapeutic Systems Inc. Private placement of convertible subordinated debentures - 100 Inhale entered into a purchase agreement providing for the sale to certain initial purchasers of $100M aggregate principal amount of convertible subordinated debentures ($109M if the overallotment option is exercised in full); the offering was made to qualified institutional buyers and a limited number of accredited investors; interest on the debentures will accrue at a rate of 6.75% per year, subject to adjustment in certain circumstances; the debentures will mature in 2006 and will be convertible into shares of Inhale's common stock at a conversion price of $32.01 per share (10/7)
InKine Pharmaceutical Inc. Private placement of common stock and warrant 2.3S and 1W 3 InKine secured $3M in a private placement consisting of 2.3M new shares of common stock and a four-year warrant for 0.8M additional shares at a strike price of $1.78; participants included placement agent Ladenburg Thalmann & Co. Inc., the Tail Wind Fund Ltd, of London, and Oxford Bioscience Partners, InKine's largest shareholder (9/21)
International Isotopes Inc. Private placement of units and placement of convertible preferred stock 1.04U (each unit consists of 1S and and 1W) 19.5 ($9.5 from units, $10 from preferred convertibles) Investors included officers, directors, previous investors and 2 investment funds; 2part private placement consisted of placement of 1.04M units, each consisting of 1 common share (at $9.10 per share) and 1 warrant to buy a common share at $10; preferred convertible stock has 5% coupon; initial conversion price is $11.86 per share; convertibles come with 0.41M warrants to buy common stock (6/3)
LeukoSite Inc. Private placement of common stock 1.5S 14.4 Placement consists of approximately 1.5M unregistered shares of common stock to Perseus Capital LLC, and HealthCare Ventures LLC (7/20)
Ligand Pharmaceuticals Inc. Exercise of warrants 2.27S 12.5 Ligand received $12.5M from institutional investors who elected to exercise early their warrants to purchase 2.27M shares of common stock prior to year-end; the warrants were issued through a Ligand/Allergan Ligand Retinoid Therapeutics Inc. 1995 public offering of 3.25M units at $10 each (1/4)
Ligand Pharmaceuticals Inc. Exchange of warrants 2.3W 13.9 Ligand received net proceeds of $13.9M from the completion of its offer to exchange warrants to purchase shares of common stock tendered with cash payments of $7.12 per warrant for shares of common stock and $1.12 per warrant (12/21)
LJL BioSystems Inc. Private placement 2.0S 7 The company sold 2M shares of unregistered common stock at $3.50 each to Bay City Capital and The Kaufmann Fund; the company will register the shares for resale; Hambrecht & Quist LLC advised the company (1/27)
Lorus Therapeutics Inc. Private placement 5.33W 1.1 Lorus placed 5.33M special warrants at US$0.20 each with 6 institutional investors; each warrant can be converted into 1 share common stock (at US$0.24 per share any time before 1/8/00) and 0.5 common share purchase warrant; Groome Capital Inc. acted as the placement agent (prices converted at a rate of C$1.51/ US$1) (1/11)
Lorus Therapeutics Inc. Private placement of warrants 30.3W C$10 (US$6.83) Lorus completed a private placement of 30.3M special warrants at a price of C$0.33 (US$0.23) per warrant; each warrant will entitle the holder to acquire, subject to adjustment, one share of common stock; HSBC Securities Inc. acted as lead agent; lead investor was Royal Bank Capital Corp. (10/28)
Martek Biosciences Corp. Private placement of shares and warrants 1.5S; warrants for 0.45S 13.5 Martek sold 1.5M shares of common stock and issued warrants to buy 0.45 shares for an aggregate purchase price of $13.5M; purchase price was $9.03 per share, reflecting 30-day price average; warrants have a 3-year term and are exercisable at $10.84; buyers are institutional investors that have previously invested in the company (6/1)
Matritech Inc. Private placement 3.1S 4 Matritech completed $4M private placement of 3.1M shares to Grethe R. Bruckner, A.B. Siemer and Zero Stage Capital VI LP (4/07)
Matritech Inc. Private placement of units 0.9 units of 2S and 1W 3.6 Undisclosed private investors invested $3.6M in the company through a private placement of 0.9M units at a price of $4 per unit; each unit consisted of two shares of common stock and a warrant to purchase one share of common stock; the warrants are exercisable at $2.20 per share for a period of two years and are callable by Matritech if certain common stock price levels are reached during the two-year period (11/18)
Maxim Pharmaceuticals Inc. Private placement of convertible preferred stock - 20 Maxim made a private placement of $20M of convertible preferred stock to a group of existing shareholders and new investors based in the U.S. and Europe; the preferred stock is convertible into shares of common stock at a fixed price of $9.73 per share, and may be converted into a total of 2.1M shares of common stock; the preferred stock has a dividend of 12%, payable in cash or in additional shares of preferred stock at the option of the holder; Maxim may call for a mandatory conversion of preferred stock into common stock after 90 days (7/26)
Maxim Pharmaceuticals Inc. Private placement of convertible preferred stock - 20.6 Maxim placed $20.6M of convertible preferred stock with a group of existing shareholders and new investors based in the U.S. and Europe; the preferred stock is convertible into shares of common stock at a fixed price of $8.90 per share, based on the average closing bid prices for the five days prior to completion of the placement; the preferred stock may be converted into a total of 2.3M shares of common stock (11/2)
Micrologix Biotech Inc. Special units financing 7.7U C$15 (US$10.1) Micrologix closed a bought-deal financing led by Yorkton Securities Inc.; other investors were TD Securities Inc., RBC Dominion Securities Inc., CIBC World Markets Inc. and CT Securities Inc.; a total of 7.7M special units were issued at a price of C$1.95 (US$1.31) per unit; each unit entitles the holder to acquire, at no additional cost, one common share of Micrologix and a one-half common share purchase warrant; each whole common share purchase warrant entitles the holder to purchase one common share of Micrologix at C$2.35 (US$1.57) for a period of 12 months from closing or, in certain circumstances, up to 24 months from closing (8/27)
Neoprobe Corp. Private placement of convertible preferred stock 0.03S 3 The private placement involved the issuance of 0.03M shares of 5% Series B convertible preferred stock, which may be converted to common stock; initial conversion price is $1.03 per share (2.9M shares); purchasers received warrants to buy 2.9M shares; a 2nd closing for the sale of an additional $3M of preferred stock may occur 4Q, at the earliest, at Neoprobe's option (3/3)
Neose Technologies Inc. Private placement of common stock 1.5S 14.25 Neose sold 1.5M shares of common stock to institutional and individual investors at $9.50 per share, the closing bid price of the stock on 6/17 (6/29)
NeoTherapeutics Inc. Private placement 1.53S 4 The company sold $4M in preferred stock to 2 institutional investors, who have the option to buy an additional $2M in preferred stock in 180 days; the first $4M in stock is convertible into common stock (for a maximum of 1.45M shares) at an initial fixed price of $13.06 per share for the 1st 90 days and thereafter at the lesser of the fixed price or at 101% of the market price; the company has the option to sell the 2nd tranche of $2M; it has similar terms except the conversion price is 125% of the market price; the investors also got 5-year warrants to buy 75,000 shares of common stock at $12.98 each (2/2)
NeoTherapeutics Inc. Private placement of common stock and warrants 0.4S, warrants for 0.08S 4 Clients of Ingalls & Snyder LLC paid $4M for 0.4M common shares and warrants to purchase 0.08M shares; for each $50, the investor received 5 common shares and 1 warrant exercisable over a 5-year period at $15 per share (5/14)
NeoTherapeutics Inc. Private placement of common stock 0.8S 10 NeoTherapeutics sold 0.8M shares of common stock to two institutional investors at $11.83 per share; in addition, the investors received five-year warrants to purchase 0.13M shares of common stock at an exercise price of $14.24 per share, and additional adjustment warrants to purchase additional shares of common stock at two reset dates, four and six months subsequent to the closing (11/19)
Neurobiological Technologies Inc. Private financing ND 1.1 Existing and new investors participated in the financing, which was managed by the company; further details ND (4/19)
Neurobiological Technologies Inc. Loan agreement - 1.5 Neurobiological's corporate collaborator, Merz & Co. GmbH, of Germany, agreed to loan the company up to $1.5M to support continuing late-stage clinical development of Memantine; the loan is interest bearing and may be converted to equity at Merz's discretion; use of the funds is restricted to support the company's Phase IIb clinical trial of Memantine for neuropathic pain (8/4)
Neurobiological Technologies Inc. Private placement of securities Units of 5S stock and 1W 4.2 Neurobiological raised $4.2M in gross proceeds from a private placement of its securities at $4 per unit; each unit consisted of five shares of common stock and a fiveyear warrant to purchase two shares of common stock exercisable at $1.75 per share; placement agent was AmeriCal Securities Inc.; existing and new investors included Paramount Capital Inc., Clarion Capital Corp. and Active Site Partners (11/11)
Neurocrine Biosciences Inc. Private placement of common stock 2.3S 42 Neurocrine sold 2.3M shares of common stock to five institutional investors at $18 per share; placement agents were FleetBoston Robertson Stephens, Deutsche Bank Alex. Brown and Prudential Vector Securities Inc. (12/23)
Nexell Therapeutics Inc. Private placement of convertible preferred stock 0.063S 63 Nexell raised $63M in a private placement of Series B preferred stock, convertible into common stock at $2.75 per share; Lehman Brothers acted as placement agent; investors included John Hancock Mutual Life Insurance Co., Metropolitan Life Insurance Co. and Massachusetts Mutual Life Insurance Co. (11/29)
Nymox Pharmaceutical Corp. Private placement of common stock ND 12 Nymox raised $12M in a private placement of common stock to institutional investors; Ladenburg Thalmann & Co. acted as placement agent (11/12)
Oncolytics Biotech Inc. (a subsidiary of Synsorb Biotech Inc.) Private placement of special warrants 1.5W C$0.9 (US$0.6) Oncolytics completed a private placement of 1.5M special warrants sold at C$0.60 (US$0.40) per warrant; each warrant is exercisable into one Oncolytics common share and one share purchase warrant; each share purchase warrant is exercisable to purchase one common share at C$0.75 (US$0.50) within two years from an initial offering; Canaccord Capital Corp. acted as agent (8/4)
Ophidian Pharmaceuticals Inc. Senior note financing - 2 Company director Rex Bates and shareholder Davis Merwin provided $2M in financing consisting of 10-year, 10% senior notes with warrants; interest payable in stock for the first 3 years and thereafter in cash; the company issued 1M 5-year warrants separately to the same investors, exercisable at $2 per share (notes can be applied to exercise of warrants) (6/7)
Organogenesis Inc. Private placement of convertible debentures - 20 Organogenesis raised $20M through private placement of $20M worth of convertible debentures at a fixed price of $15 per share; the debentures have attached 0.4M 5-year warrants at $22.50 per share (4/1)
Orphan Medical Inc. Private placement of convertible stock and debt financing - 5 Orphan completed a $5M financing with UBS Capital consisting of $2.95M of Series B convertible preferred stock and $2.05M of debt; the preferred stock may be converted, prior to August 2, 2009, into common shares at a price of $6.50 per share; the debt carries an interest rate of 7.5% and matures on August 2, 2002; in connection with the financing, UBS Capital also received two seven-year warrants; one of the warrants entitles UBS to receive, upon payment of the $2.05M exercise price, either $2.05M of Series C convertible preferred stock, or 0.3M shares of Series D non-voting preferred stock; the other warrant, issued in relation to the debt financing, entitles USB to purchase 0.3M shares of Series D non-voting preferred stock at an exercise price of $4.25 per share; Orphan can require the exercise of the warrants under certain conditions (8/2)
Ortec International Inc. Private placement of common stock 1.6S 9 Ortec received $9M from two institutional funds through a private placement of common stock; Pequot Capital Management, of Westport, Conn., invested $7M for which it received 1.2M shares; S. Squared Technology Corp., of New York, invested $2M for which it received 0.36M shares; the company acted as its own placement agent (12/29)
Oxford BioMedica plc Rights issue 23.7S 5.8 Oxford to offer up to 23.7M shares to qualifying shareholders at $0.23 per share, on a 1-for-5 basis (3/3)
Oxford Glycosciences plc Sale of biochemicals business - 2.1 Glyko Inc. agreed to pay $2.1M to acquire OGS' biochemicals business; payment is in 3 stages: $0.75M due immediately, $0.75M due upon completion of certain technology transfers, and $0.6M due on 2nd anniversary of signing, contingent upon sales and inventory factors (5/4)
Palatin Technologies Inc. Private placement ND 3.8 Palatin sold $3.8M in unregistered common shares and warrants; each share has a detachable 5-year warrant to purchase 1 share common stock at market; the securities were sold under a Regulation D exemption; the company will register the shares for resale (2/9)
Paracelsian Inc. Private placement ND 0.4 Paracelsian completed a private placement in the amount of $0.4M; under the terms of the placement, warrants for substantial additional investment in the company are provided; further details ND (8/3)
Peptide Therapeutics Group plc Rights offering 29.3S 37.5 The company raised $37.5M gross ($33.8M net) by selling 29.3M new shares of common stock to current shareholders at $1.28 each in a 4-for5 rights offering; current shareholders bought 0.91M shares and BT Alex. Brown International underwrote the rest (prices converted at a rate of 0.609/$US1) (2/16)
Phage Therapeutics International Inc. Private placement 3.0S 0.2 The company sold an additional 3M common shares for $0.05 each in an extension of its 12/98 Regulation D financing; in all, it sold 7M shares at $0.05 each for total proceeds of $0.35M (2/18)
Phage Therapeutics International Inc. Private placement of common stock 0.75MS 0.15 Phage completed private placement of 0.75 common shares for $0.20 each to raise $0.15M (3/10)
Precision Biochemicals Inc. (a subsidiary of IGT Pharma Inc.) Private placement of equity - C$0.5 (US$0.34) The Biopharmaceutical Innovation Resource Fund invested C$0.5M (US$0.34) in Precision in exchange for a 40% equity position in the company (9/9)
Procyon Biopharma Inc. Private placement of common stock 12S 2 Procyon completed the second phase of a private financing, the first phase of which was completed in October; the company issued 12M shares of common stock at $0.25 per share to European and other investors, and to T2C2 and Innovatech du Grand Montreal, Quebec-based venture capital firms (11/22)
Protein Polymer Technologies Inc. Private placement of convertible preferred stock 0.035S 1.8 Protein Polymers completed an initial closing of a private placement of Series G convertible preferred stock with a small group of accredited and institutional investors at $100 per share; each share can be converted at any time into common stock at a price of $0.50 per share, subject to certain antidilution adjustments; each share of preferred stock also receives a common stock warrant, exercisable for 12 months, that allows the holder to acquire 200 shares of common stock at $0.50 per share (8/17)
Repligen Corp. Private placement of common stock 3.6S 9 Repligen raised $9M through placement of 3.6M shares at $2.50 per share; investors included Wellington Management Company LLP; Paramount Capital acted as adviser (5/17)
RiboGene Inc. Loan - 5 RiboGene completed a $5M working capital loan from Venture Banking Group, a division of Cupertino National Bank; the $5M note is due in 3 years (1/5)
SangStat Medical Corp. Convertible debt financing - 10 SangStat completed convertible debt financing of $10M in aggregate principal amount of securities with an undisclosed financial institution; the securities have a maturity of 5 years and are convertible at any time prior to maturity into approximately 0.5M shares of common stock, representing a conversion price of approximately $20 per share (4/5)
SciClone Pharmaceuticals Private placement of shares and warrants 1.37U (each consisting of one share and one warrant to purchase one share) 2 Private placement with institutions and accredited individual investors; the placement consists of approximately 1.37M units, each accompanied by a warrant to purchase one share of common stock; each unit was priced at $1.46, a 20% premium over the market price on the closing date (7/6)
SciClone Pharmaceuticals Private placement of shares and warrants 2.5U (each unit consists of 1S and 1W) 4 Private placement with institutional investors, led by Brown Simpson Asset Management and New York Life Insurance Company, consisted of units of approximately 2.5M shares of common stock, each accompanied by a warrant to purchase one share of common stock (7/22)
Sugen Inc. Private placement of convertible notes - 28 Sugen privately placed $28M principal amount of 12% senior convertible notes due 2002; notes convertible to shares at fixed price of $20.50 per share; interest may be paid in common stock or cash at the company's option; purchasers also received warrants to purchase additional $21M principal amount of the notes, which mature on 3rd anniversary of issuance; Diaz & Altschul Capital LLC served as placement agent; Delta Opportunity Fund Ltd. was lead investor (3/22)
SuperGen Inc. Private placement ND 16.6 SuperGen closed a private placement transaction with Capital Research & Management Co.; further details ND (9/7)
Theratechnologies Private placement of units 0.6U C$6 (US$4.1) Fidelity Investments purchased 0.6M units (C$10 each) for a total of C$6M (US$4.1M); each unit consists of 1 share and 1 warrant for the purchase of 2.5 shares of Ecopia Biosciences held by Theratechnologies, or in certain circumstances, 1/3 of a share of Theratechnologies (corresponding to C$15 a share); LTvesque Beaubien Geoffrion Inc. arranged the placement (5/28)
Theratechnologies Exercise of warrants 0.5W 2.6 Theratechnologies received proceeds of $2.6M from the exercise of 0.5M share purchase warrants; each warrant entitled its holder to purchase one common share for $5 (12/2)
Titan Pharmaceuticals Inc. Private placement 2.25S 6.2 Titan sold 2.25M shares of common stock at $2.76 each to 2 members of the company's board of directors as well as institutional investors OrbiMed Advisors LLC, Biotechnology Value Fund LP, Emerging Growth Management Co. and Ursus Capital LP Evolution Capital Inc.; Leerick, Swann & Co. acted as the placement agent for part of the transaction (1/28)
Transkaryotic Therapies Inc. Private investment in a public entity (PIPE) 3.3S 132 Transkaryotic entered into purchase agreements for the sale of 3.3M shares of common stock in a PIPE financing to selected institutional and other accredited investors; share price was $40; Pacific Growth Equities acted as placement agent (10/29)
United Therapeutics Corp. Private placement of common stock 2.5S 80 UTC entered definitive agreements for the sale of 2.5M shares of common stock to institutional investors at $32 per share; Prudential Vector Healthcare Group acted as placement agent (12/22)
U.S. Bioscience Inc. Private placement 2.69S 20 U.S. Bioscience issued 2,686,728 shares of common stock at $7.44 each (average closing price over 30-day period) to investors led by Domain Partners IV LP and Proquest Investments LP (which together now own an 11% stake in the company); the investors also got 3-year warrants to buy 537,346 shares of common stock at $11.17 each; the investors will hold the shares for at least 1 year (1/28)
VaxGen Inc. Private placement of common stock ND 25 VaxGen completed a private placement of common stock to Vulcan Ventures Inc., the investment organization of Paul G. Allen, chairman of Vulcan; further details ND (10/12)
Vion Pharmaceuticals Inc. Direct private placement 0.89S 4 Vion raised $4M through the sale of 0.89 common shares to Elliott Associates LP, Westgate International LP, United Equities Commodities Co., Wechsler and Co. Inc., Kleinwort Benson Ltd., and Winchester Capital Healthcare Partners LLC (4/23)
Viragen Inc. Private placement ND 9 Viragen signed a preliminary agreement with a single investor for $9M in funding; the investor will buy newly issued shares of common stock (at market; no discount) in 3 tranches of $3M each (2/18)
Viragen Inc. Private placement 3S and additional convertible notes 3 Subscription agreements provide for the direct purchase of Viragen common stock at market price pursuant to which Viragen will register and issue about 3M shares for 2.5M; the 3 investors may sell no more than 0.125M shares each per quarter; company also received $0.5M balance of the first tranche for which it has issued 8% convertible notes (6/14)
ViroPharma Inc. Private placement of preferred shares 2.3S 14.3 Perseus-Soros BioPharmaceutical Fund LP purchased 2.3M preferred shares (5% annual dividend), convertible on a 1-for-1 basis to common stock; Perseus-Soros also receives warrants to buy up to 0.595M common shares at $9.53 per share (5/6)
Visible Genetics Inc. Equity investment in exchange for preferred convertible stock and warrants 1.1W C$30 (US$20) Visible Genetics received C$30M in equity financing from E.M. Warburg, Pincus & Co. LLC in exchange for which Warburg received preferred stock convertible at C$11 per share, and 1.1M warrants exercisable for a 4-year period at C$12.60 per share (7/16)
Xenova Group plc Private placement of shares, exercising of warrants 2.2S; 5W #6.1 (US$9.9) Private placement of 2.2M shares with institutional shareholders at 85 pence per share, raising a total of #1.9M before expenses; Nomura International plc disposed of 3.2M Xenova shares to institutional investors at 85 pence per share, enabling its early exercise of 5M Xenova warrants at 70 pence per warrant; four additional institutional investors and certain members of Xenova's board of directors announced their intention to exercise their Xenova warrants which, with the exercise of warrants by Nomura, will provide Xenova with an additional 4.2M (7/1)
Xenova Group plc Net cash payment for sale of assets - #0.24 (US$0.38) Exelixis Pharmaceuticals Inc. will acquire the majority of assets of MetaXen LLC, a subsidiary of Xenova, including facilities, equipment and employees; Xenova will receive a net cash payment of #0.24M (US$0.38M), as well as retain ownership of certain intellectual property developed by MetaXen relating to lead drug optimization, drug profiling and predictive modeling (7/12)
Xoma Ltd. Private placement 2.0S 12 Xoma sold 2M shares of common stock at $6 each (60% premium over market) to 2 institutional investors, Advantage Fund II Ltd. and Koche Investment Group Ltd.; the shares will be held in an escrow account until sold; beginning 8/31/99, the number of shares in escrow may be adjusted at 90-day intervals based on an 11% discount from market price at the time; the investors also got 5-year warrants to buy 0.24M shares at 60% premium to market; CIBC Oppenheimer served as an advisor to Xoma (1/29)
Xoma Ltd. Private placement of common stock 3S 17.4 Private placement of 3M common shares for gross proceeds of $17.4M; Sutro & Co. and Arnhold & S. Bleichroeder served as placement agents (7/22)
Note: ND = Not disclosed, reported and/or available
Note: S = Shares
Note: U = Units
Note: W = Warrants
Note: The financings in this chart include loans, bridge financings, PIPE financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements.